132 results on '"Huang, Huiyao"'
Search Results
2. Tunable swelling features in poly(ionic liquid)s for intensified catalytical synthesis of ethyl methyl carbonate with high yield and selectivity
3. A call to rethink the necessity of and challenges facing academic research organizations in the new era of drug innovation in China
4. Comparison of the new self-contained darkroom refractive screener versus table-top autorefractor and cycloplegia retinoscopy in detecting refractive error
5. Comparing a PD-L1 inhibitor plus chemotherapy to chemotherapy alone in neoadjuvant therapy for locally advanced ESCC: a randomized Phase II clinical trial: A randomized clinical trial of neoadjuvant therapy for ESCC
6. Unfair older patients restriction in cancer drug trials in mainland China and corresponding solution
7. Rare tumors: a blue ocean of investigation
8. HLA and tumour immunology: immune escape, immunotherapy and immune-related adverse events
9. Growing research and development of targeted anticancer drugs in China
10. The reliability and integrity of overall survival data based on follow-up records only and potential solutions to the challenges
11. Fine-Tuning Electron–Donor Capability in the Basic Anion of Poly(ionic liquid) Frameworks for Revolutionizing Catalytic Synthesis of Ethyl Methyl Carbonate with Both Ultrahigh Catalytic Activity and Selectivity
12. Accelerating the integration of China into the global development of innovative anticancer drugs
13. Nanoparticle-based medicines in clinical cancer therapy
14. The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
15. Unblinding at disease progression in double-blinded randomized controlled cancer drug clinical trials: A controversy requires more attention
16. Advances on anticancer new drugs in China and the USA in 2020: from ongoing trial to drug approval
17. Unveiling quality of clinical trial in China: from concern to confirmation
18. Quantitative evaluation of the impact of relaxing eligibility criteria on the risk–benefit profile of drugs for lung cancer based on real‐world data.
19. Seven-year exclusivity and beyond for drugs of rare diseases in China
20. Adverse events of PD-(L)1 inhibitors plus anti-VEGF(R) agents compared with PD-(L)1 inhibitors alone for cancer patients: a systematic review and meta-analysis
21. Outcome measures of phase III anticancer drug trials in China
22. Geriatric drug trials on solid tumor are scarce worldwide
23. Additional file 4 of Comparing a PD-L1 inhibitor plus chemotherapy to chemotherapy alone in neoadjuvant therapy for locally advanced ESCC: a randomized Phase II clinical trial
24. Additional file 1 of Comparing a PD-L1 inhibitor plus chemotherapy to chemotherapy alone in neoadjuvant therapy for locally advanced ESCC: a randomized Phase II clinical trial
25. Additional file 2 of Comparing a PD-L1 inhibitor plus chemotherapy to chemotherapy alone in neoadjuvant therapy for locally advanced ESCC: a randomized Phase II clinical trial
26. Additional file 3 of Comparing a PD-L1 inhibitor plus chemotherapy to chemotherapy alone in neoadjuvant therapy for locally advanced ESCC: a randomized Phase II clinical trial
27. Targeting rare tumors: new focus for clinical research in China
28. Association between germ-line HLA and immune-related adverse events
29. Availability and Affordability of Oncology Drugs in 2012-2021 in China and the United States
30. Identification of Tumor Antigens and Immune Subtypes of Malignant Mesothelioma for mRNA Vaccine Development
31. Additional file 1 of The global landscape of neoadjuvant and adjuvant anti-PD-1/PD-L1 clinical trials
32. Targeting rare tumors: new focus for clinical research in China.
33. Landscape and perspectives of macrophage -targeted cancer therapy in clinical trials
34. The Burden of Rare Tumors in China: Results of a Population-Study
35. The Landscape of Cell and Gene Therapies for Solid Tumors
36. Evolution of global clinical trials with adaptive design
37. Molecular Mechanisms of Resistance to Osimertinib from Liquid Biopsies of Plasma and Pleura Effusion in EGFR Mutant NSCLC Patients
38. Effects of the 6VS.6AL translocation on agronomic traits and dough properties of wheat
39. Whole-exome Sequencing Reveals Genetic Underpinnings of Tongue Carcinoma in Chinese Population
40. Temporal trends and geographic differences of insurance coverage for cancer drug trials in mainland China
41. Abstract LB-310: Whole-exome sequencing reveals genetic underpinnings of salivary adenoid cystic carcinoma and tongue carcinoma in Chinese population
42. Expenditure and Financial Burden for Stomach Cancer Diagnosis and Treatment in China: A Multicenter Study
43. Whole-exome sequencing reveals genetic underpinnings of salivary adenoid cystic carcinoma in the Chinese population
44. The prevalence of targetable genomic alterations is substantially high in rare tumors.
45. Comprehensive Genomic Profiling of Rare Tumors: Routes to Targeted Therapies
46. Health‐related quality of life in patients with esophageal cancer or precancerous lesions assessed by EQ‐5D: A multicenter cross‐sectional study
47. Medical expenditure of hepatitis B virus infection and its impact factors analysis in Qidong, Jiangsu Province
48. Temporal trends and geographic differences of insurance coverage for cancer drug trials in mainland China
49. A label-free electrochemical platform for the highly sensitive detection of hepatitis B virus DNA using graphene quantum dots
50. Effects of the 6VS.6AL translocation on agronomic traits and dough properties of wheat
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.